MP39-18 ANTICOAGULANT AND ANTIPLATELET MEDICATIONS AND THEIR ASSOCIATION WITH HEMATURIA-RELATED COMPLICATIONS: A FIVE-YEAR SINGLE-INSTITUTION RETROSPECTIVE STUDY

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP39-18 ANTICOAGULANT AND ANTIPLATELET MEDICATIONS AND THEIR ASSOCIATION WITH HEMATURIA-RELATED COMPLICATIONS: A FIVE-YEAR SINGLE-INSTITUTION RETROSPECTIVE STUDY Joshua Hayden, Jason Nelson, Edward Frankenberger, and Alex Vanni Joshua HaydenJoshua Hayden More articles by this author , Jason NelsonJason Nelson More articles by this author , Edward FrankenbergerEdward Frankenberger More articles by this author , and Alex VanniAlex Vanni More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003277.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Anticoagulant and antiplatelet medications are commonly prescribed and associated with urologic bleeding. Our objective was to evaluate the association of anticoagulant and antiplatelet medications with hematuria-related complications. Our hypothesis was that rivaroxaban has a higher risk of bleeding complications compared to other anticoagulant and antiplatelet medications. METHODS: Individuals prescribed anticoagulant and/or antiplatelet medications between October 2015 and May 2021 at our institution were included. Baseline demographics were collected. Hematuria-related complications, defined as either emergency department visits for gross hematuria, hospital admissions for gross hematuria, or urologic procedures to manage gross hematuria were then measured using incidence density rates and a negative binomial regression model. RESULTS: Of the 119,528 patients included, 10,601 (8.9%) were exposed to rivaroxaban and 108,927 (91.1%) were exposed to non-rivaroxaban anticoagulant/antiplatelet medications. Those unexposed to rivaroxaban had lower rates of any hematuria-related complications (adjusted rate ratio (aRR) 0.72; 95% confidence interval (CI) 0.65 to 0.79), had fewer hospitalizations (aRR 0.77; 95% CI 0.64 to 0.93) and required fewer urologic procedures to manage gross hematuria (aRR 0.54; 95% CI 0.47 to 0.64) compared to those exposed to rivaroxaban. Compared to rivaroxaban, enoxaparin had the highest rate of any hematuria-related complications (aRR 2.74; 95% CI 2.43 to 3.10). CONCLUSIONS: Enoxaparin was associated with the greatest risk of hematuria-related complications. Among oral antiplatelet and anticoagulant medications, exposure to rivaroxaban was significantly associated with higher rates of hematuria-related complications, including hospitalization and the need for urologic procedures to manage gross hematuria. Source of Funding: Lahey Hospital and Medical Center Department of Urology. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e543 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Joshua Hayden More articles by this author Jason Nelson More articles by this author Edward Frankenberger More articles by this author Alex Vanni More articles by this author Expand All Advertisement PDF downloadLoading ...